research reports and media, page-457

This below is from the MST report - I wasn't aware that the Bene exclusive supply contract covered only ANZ and some smaller Asian markets. I don't recall this being flagged previously, and understood/assumed that the contract applied worldwide. An exclusive supply contract that doesn't cover the USA is not necessarily ideal, to put it mildly.

"Paradigm has negotiated supply contact with German pharmaceutical company, bene pharmaChem, for the supply of FDA-approvedcGMP-grade PPS. The supply agreement is for an initial term of 10 years with an option for an extension of a further 10 years providedthat within the first 10 years Paradigm has obtained regulatory approval for sale of a product incorporating PPS. The contract covers an exclusive supply for Bone Marrow Edema, Asthma, Rhinitis and chronic obstructive pulmonary disease inAustralia, New Zealand and a number of the smaller Asian markets. (Philippines, Indonesia, Thailand, Singapore, Vietnam, Taiwan,Myanmar (Burma), Brunei (Darussalam), Cambodia, Laos and Malaysia). In other markets, bene has the right to decide if it will supply and whether it will be exclusive."

Apologies if I've missed something...